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ABSTRACT
We report the results of reduced-intensity conditioning allogeneic stem cell transplantation (allo-RIC) in
patients with advanced Hodgkin lymphoma (HL). Forty patients with relapsed or refractory HL were homo-
geneously treated with an RIC protocol (fludarabine 150 mg/m2 intravenously plus melphalan 140 mg/m2
intravenously) and cyclosporin A and methotrexate as graft-versus-host disease (GVHD) prophylaxis. Twenty-
one patients (53%) had received >2 lines of chemotherapy, 23 patients (58%) had received radiotherapy, and
29 patients (73%) had experienced treatment failure with a previous autologous stem cell transplantation.
Twenty patients (50%) were allografted in resistant relapse, and 38 patients received hematopoietic cells from
an HLA-identical sibling. Five patients (12%) died from early transplant-related mortality (before day 100
after allo-RIC). One-year transplant-related mortality was 25%. Acute GVHD developed in 18 patients (45%).
Chronic GVHD developed in 17 (45%) of the 31 evaluable patients. The response rate 3 months after the
allo-RIC was 67% (21 [52%] complete remissions and 6 [15%] partial remissions). Eleven patients received
donor lymphocyte infusions (DLIs) for disease relapse. The response rate after DLI was 54% (3 complete
remissions and 3 partial remissions). Overall survival (OS) and progression-free survival (PFS) were 48% 
10% and 32%  10% at 2 years, respectively. Refractoriness to chemotherapy was the only adverse prognostic
factor for both OS (63% 12% versus 35% 13%; P .05) and PFS (55% 16% versus 10% 9%; P .006).
For patients with failure of a prior autologous hematopoietic stem cell transplantation, results were especially
good for those who experienced late relapses (>12 months: 2-year OS and PFS were 75%  16% and 70% 
18%, respectively). These data suggest that allo-RIC is feasible in heavily pretreated HL patients and has an
acceptable early transplant-related mortality. Results are better in patients allografted in sensitive disease. Both
responses observed after the development of GVHD and DLI may suggest a graft-versus-HL effect. Allo-RIC
has to be considered an effective therapeutic approach for patients who have had treatment failure with a
previous autologous hematopoietic stem cell transplantation.
© 2006 American Society for Blood and Marrow Transplantation
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Reduced-Intensity Conditioning Allogeneic Transplantation for Hodgkin Lymphoma
BNTRODUCTION
Approximately 80% of patients with advanced
odgkin lymphoma (HL) who are treated with mod-
rn chemotherapy associated or not with irradiation
an now be cured [1,2]. Unfortunately, patients who
elapse or prove refractory to ﬁrst-line therapy do
igniﬁcantly worse [3,4]. High-dose chemotherapy/
adiotherapy (RT) followed by transplantation of au-
ologous hematopoietic stem cells (ASCT) is the stan-
ard of care for all patients with relapsed or refractory
L [5,6].
The role of allogeneic stem cell transplantation
allo-SCT) in patients with relapsed or refractory HL
as been highly controversial. Although several series
ave suggested that allo-SCT seems to be associated
ith a clinically signiﬁcant graft-versus-HL effect and
lower relapse rate with respect to ASCT [7-10],
etrospective analyses from the international Bone
arrow Transplant Registry [11] and the European
roup for Blood and Marrow Transplantation [12]
emonstrate disappointing results with allo-SCT in
L because of an extremely high transplant-related
ortality (TRM) that is mainly associated with acute
nd chronic graft-versus-host disease (GVHD) and
oncomitant infectious episodes.
Reduced-intensity conditioning allo-SCT (allo-
IC) is currently being evaluated in patients with
ematologic malignancies who are considered poor
andidates for conventional allo-SCT because of age
r associated comorbidities [13-15]. The rationale for
llo-RIC relies on previous observations that adoptive
ransfer of alloreactive donor lymphocytes may erad-
cate refractory or recurrent disease [16-18]. These
IC protocols could be of beneﬁt for relapsed and
efractory HL patients by reducing the high TRM
lassically associated with conventional allo-SCT,
hus improving the long-term outcome in this group
f poor-prognosis patients. Several groups have al-
eady reported their results with allo-RIC in relapsed
r refractory HL [19-23]. Most of these series are
haracterized by a low number of patients and are
eterogeneous in terms of nonmyeloablative protocols
nd GVHD prophylaxis, and follow-up is usually
hort. To explore the efﬁcacy of this approach, we
nalyzed the results of a group of 40 patients with
elapsed or refractory HL who were treated with a
omogeneous RIC regimen and included in a pro-
pective multicenter Spanish protocol.
ATIENTS AND METHODS
atient Selection and Characteristics
We have analyzed the data of 40 patients with
elapsed or refractory HL who underwent a allo-RIC
n 13 transplant centers in Spain between June 1999
nd January 2004. Eligibility criteria included the di- D
B & M Tgnosis of primary refractory HL or relapsed HL
relapse after a ﬁrst complete remission [CR] with
oor-prognostic factors at relapse or multiple relapses,
ncluding relapse after an ASCT), age 65 years, and
vailability of an HLA-compatible sibling or an HLA-
ompatible unrelated donor. Additional eligibility re-
uirements included the absence of active bacterial or
ungal infections at the time of transplantation and
reserved cardiac (ejection fraction 35%) and pul-
onary (forced vital capacity 30%) functions. Pa-
ients were not eligible if there was serologic evidence
f infection with the human immunodeﬁciency virus.
atients gave written informed consent for inclusion
n the protocol, which was approved by all local ethical
eview boards as well as the Spanish drug agency.
Clinical characteristics of the patients included in
he study at diagnosis, before the allo-SCT, and at
ransplantation are shown in Tables 1 and 2, respec-
ively. There were 24 male and 16 female patients
ith a median (range) age at diagnosis of 31 years
16-53 years) and of 35 years (18-55 years) at the time
f allo-RIC (8 patients [20%] were 45 years old). Of
ote, the population of patients included in the study
ad been very heavily pretreated. The median time
etween diagnosis and allo-RIC was 37 months
range, 11-300 months). Twenty-one patients (53%)
ad received more than 2 lines of chemotherapy be-
ore allogeneic transplantation, 23 patients (58%) had
een treated with complementary RT on previously
nvolved areas during ﬁrst-line therapy, and 29 pa-
able 1. Characteristics of the Patients at Diagnosis
nd before Transplantation
Characteristic Data
ex
Male 24 (60)
Female 16 (40)
ge, y, median (range) 31 (16-53)
istological characteristics
Nodular sclerosis 27 (88)
Mixed cellularity 3 (7)
Lymphocyte depletion 2 (5)
nn Arbor stage
I or II 16 (40)
III or IV 24 (60)
B” symptoms 25 (63)
irst-line therapy
MOPP-like regimens 5 (12)
Doxorubicin-containing regimens 31 (78)
Other protocols 4 (10)
omplementary radiotherapy 23 (58)
revious ASCT 29 (73)
SCT to allo-RIC interval, mo median (range) 17 (4-146)
o. lines of therapy before allo-RIC
0-2 lines 19 (47)
>2 lines 21 (53)
SCT indicates autologous stem cell transplantation; allo-RIC,
allogeneic stem cell transplantation after a reduced-intensity
conditioning protocol.ata are n (%) unless otherwise noted.
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1ients (73%) had previously experienced a failed
SCT. Of the last group, 10 patients (29%) had a
R after ASCT of 1 year, and the remaining 19
atients (71%) relapsed in the ﬁrst year after autol-
gous transplantation. There were no previous sig-
iﬁcant comorbidities in the group of patients in-
luded in the protocol.
onditioning Regimen and GVHD Prophylaxis:
upportive Care—Donor Lymphocyte Infusions
fter the Allogeneic Procedure
All patients received a homogeneous conditioning
egimen that consisted of the combination of ﬂudara-
ine 30 mg/m2 intravenously for 5 days followed by
elphalan 140 mg/m2 intravenously divided into 2
able 2. Characteristics of the Patients and Donors at Allo-RIC
Characteristic Data
iagnosis to allo-RIC interval, mo, median (range) 37 (11-300)
ge, y, median (range) 35 (18-55)
>45 y 8 (20)
M involvement 3 (7.5)
COG status >2 6 (15)
eason for inclusion in the prospective protocol
Primary refractory disease 4 (10)
First relapse with 1 or more poor-prognostic
factors* 2 (5)
>2 relapses 6 (12)
Relapse after an ASCT 29 (73)
isease status at allo-RIC
Sensitive disease 20 (50)
CR 7 (17)
Sensitive relapse 11 (28)
Untreated relapse 2 (5)
Resistant disease 20 (50)
onor age, y, median (range) 36 (17-63)
onor sex
Male 19 (47)
Female 21 (53)
onor-recipient sex matching
D (M) ¡ R (M) 11 (28)
D (M) ¡ R (F) 8 (20)
D (F) ¡ R (M) 13 (32)
D (F) ¡ R (F) 8 (20)
MV status (D and R)
Both negative 4 (10)
Other combinations 36 (90)
ype of donor
HLA-compatible sibling 37 (93)
Mismatched sibling 1 (2)
HLA-compatible URD 2 (5)
tem cell source for allo-RIC
BM 37 (93)
PB 3 (7)
ata are n (%) unless otherwise noted.
llo-RIC indicates allogeneic stem cell transplantation after a re-
duced-intensity conditioning protocol; CR, complete remission;
ASCT, autologous stem cell transplantation; ECOG, Eastern
Cooperative Oncology Group; URD, unrelated donor; D, do-
nor; R, recipient; BM, bone marrow; PB, peripheral blood.
Adverse prognostic factors at ﬁrst relapse: ﬁrst CR 12 months,
stage IV at relapse, B symptoms, and hemoglobin 105 g/L.oses. In addition, 3 patients, 1 allografted from a 1 
74ntigen–mismatched related donor and 2 allografted
rom HLA-compatible unrelated donors, received
abbit antilymphocyte globulin (2.5 mg/kg intrave-
ously for 3 consecutive days) as part of the condi-
ioning regimen.
Hematopoietic stem cells were infused on day 0.
hen peripheral blood (PB) was used as the source of
ematopoietic stem cells, leukaphereses were per-
ormed on days 0 and 1 if necessary to infuse a min-
mum number of 2.0  106 CD34 cells per kilogram
f body weight to the patient. The median number
range) of PB CD34 cells infused was 6.5  106/kg
2.1-14.5  106/kg).
Acute and chronic GVHD were graded by follow-
ng established criteria [24,25]. GVHD prophylaxis
onsisted of the combination of cyclosporin A (CsA)
mg/kg intravenously starting on day 1. In the
bsence of grade II or greater acute GVHD, CsA was
apered 10% weekly starting on day 90 after the
llo-RIC and was discontinued by day 150. Metho-
rexate (MTX) was given at 10 mg/m2 intravenously
n days 1, 3, and 6, followed by folinic acid
escue.
All patients were treated in individual rooms with
everse-isolation protective measures during neutro-
enia. Antimicrobial prophylaxis was administered ac-
ording to the local standard practice guidelines of the
espective institutions.
Patients with relapsed or progressive disease after
ransplantation or those who did not evolve to 100%
onor chimerism in the absence of grade II or higher
cute GVHD were treated with rapid discontinuation
f systemic immunosuppression to initiate graft-ver-
us-HL effects. In the absence of disease response and
rade II or higher acute GVHD, patients were con-
idered eligible for donor lymphocyte infusions
DLIs). An escalated dose regimen starting at 1  107
D3 T cells per kilogram was used in all patients.
onor lymphocytes were infused at intervals of 2
onths up to a dose of 5  108 CD3 T cells per
ilogram.
himerism Analyses
For chimerism analyses, nucleated cells were iso-
ated from the marrow, T cells, and granulocytes from
he PB on days 28, 100, and 180 after the allo-RIC
rocedure or when necessary (if clinically indicated).
ercentages of donor-host chimerism were evaluated
y means of a polymerase chain reaction–based am-
liﬁcation of variable number tandem repeat se-
uences unique to donors and hosts [26,27]. Complete
onor chimerism was deﬁned as 100% donor cells,
hereas mixed chimerism indicated the presence of
1% recipient cells in the sample analyzed.
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Reduced-Intensity Conditioning Allogeneic Transplantation for Hodgkin Lymphoma
Btudy Definitions: Evaluation of Response
Patients were staged according to the Ann Arbor
ystem [28] and radiologically evaluated by means of
omputed tomographic scan and gallium 67 gamma-
raphy. Patients were deﬁned as having primary re-
ractory disease if they had received induction chemo-
herapy, with or without salvage therapy, and did not
chieve a partial response (PR) or CR. A sensitive
elapse was deﬁned as a reduction of 50% of the
idimensional measurements of the disease with the
se of conventional salvage chemotherapy or RT.
esistant relapse was deﬁned as a 50% reduction in
he size of the tumor with the use of conventional
alvage chemotherapy.
Patients were clinically staged at the time of allo-
IC, on day 90 after the procedure, every 6 months
or the ﬁrst 2 years, and then yearly or as clinically
ndicated. Patients who received DLIs for disease re-
apse or progression were also evaluated 1 month after
LI. Patients who survived 90 days after allo-RIC
ithout evidence of tumor by clinical and radiologic
valuation were classiﬁed as having CR. Patients with
mall residual radiographic abnormalities that did
ot progress for 6 months after transplantation were
lso classiﬁed as being in CR. Partial remission was
eﬁned as a 50% reduction of pretransplantation
easurable disease for at least 1 month. Patients
ho achieved a 50% tumor reduction after ASCT
ere considered as nonresponders according to the
stablished criteria [29]. Nonhematologic toxicities
hat developed after the allo-RIC procedure were
valuated according to the World Health Organiza-
ion common toxicity criteria.
tatistical Methods
Survival analyses were performed according to the
aplan-Meier method [30]. Overall survival (OS) was
alculated in months from the date of autologous stem
ell reinfusion to the date of death from any cause, and
urviving patients were censored at last follow-up. Dis-
ase-free survival was calculated from transplantation
ntil disease progression for patients who achieved a
R after transplantation and also for patients who
eached CR after DLI. Patients who experienced
RM and those who were still alive without progres-
ion at the time of reporting were censored at death
nd at last follow-up, respectively. Event-free survival
EFS) was calculated from transplantation until dis-
ase progression or death, and patients who did not
each a disease response (CR or PR) at any time after
ransplantation were considered events. Overall TRM
as deﬁned as death from any cause other than HL
nd was calculated by using a cumulative incidence
ethod. For the purpose of this analysis, TRM was
ivided into early TRM (death from any cause other
han lymphoma within the ﬁrst 100 days after the p
B & M Tllo-RIC) and late TRM (death from any cause other
han lymphoma beyond the ﬁrst 100 days after the allo-
eneic procedure). Acute GVHD incidence was also
alculated by using a cumulative incidence method in
atients who survived beyond day 21 after allo-RIC.
he incidence and time of onset of chronic GVHD
ere calculated in patients followed up for at least 90
ays.
Comparison of the survival curves in univariate
nalysis was performed by using the log-rank test [31].
nalysis of prognostic factors inﬂuencing both CR
nd TRM rates was performed by Fisher exact test and
ogistic regression analysis.
Multivariate analysis was performed by using a
orward stepwise Cox proportional hazards model.
he prognostic factors analyzed for all survival end
oints were the time interval between diagnosis and
llo-RIC (36 versus 36 months), the number of
ines of therapy before transplantation (2 versus 2
ines), previous ASCT (no versus yes), complementary
T before allo-RIC (no versus yes), Eastern Cooper-
tive Oncology Group status at allo-RIC (2 versus
2), disease status at allo-RIC (sensitive versus resis-
ant disease), sex mismatch between donor and recip-
ent (female to male versus other combinations), and
ytomegalovirus (CMV) serology for both donor and
ecipient (donor and recipient CMV versus other
ombinations).
All P values reported are 2 sided, and statistical
igniﬁcance was deﬁned as a P value .05. The sta-
istical analyses were computed with SPSS statistical
oftware (SPSS Inc., Chicago, IL).
ESULTS
ngraftment and Nonhematologic Toxicities
All patients but 1, who did not have recovery of
eutrophil counts 0.5  109/L and was classiﬁed as
primary graft failure, presented an early and sus-
ained engraftment after transplantation. The median
ime for 0.5  109/L granulocytes in the PB was
5 days (range, 10-26 days), and for 20  109/L and
0  109/L platelets, the median times were 11 days
range, 8-38 days) and 15 days (range, 11-49 days),
espectively.
All the patients except for the 1 who developed a
rimary graft failure and had an autologous recovery
fterward presented with 100% donor chimerism on
ay 30 after transplantation. Full donor chimerism
as observed during the follow-up of all the patients,
nd no case of secondary or late graft failure was
eported in our series.
The most frequently observed nonhematologic
oxicity was gastrointestinal; 18 (45%) patients expe-
ienced grades II to IV oral mucositis, and 7 (17%)
atients required total parenteral nutrition during the
175
i
u
m
s
m
I
d
m
i
(
s
c
i
a
p
(
a
2
t
T
1
e
e
o
C
T
t
p
p
s
T
m
c
i
4
R
a
a
p
f
w
7
a
f
s
D
b
T
1
tF
r
T
S
S
M
O
E
P
T
E
C
I. Alvarez et al.
1mmediate posttransplantation period. Grade II to IV
pper gastrointestinal toxicity (nausea and vomiting),
ainly related to the conditioning protocol, was ob-
erved in 8 (20%) patients. No cardiac, renal, or pul-
onary toxicity was observed.
nfectious Complications and GVHD
Thirty-one patients (77%) presented with fever
uring the neutropenic period; it was documented
icrobiologically in 14 cases (45%). Early infections
ncluded 8 cases of bacteremia, 4 cases of pneumonia
3 of unknown origin), 1 case of endocarditis, 1 case of
yncytial respiratory virus infection, and 1 Escherichia
oli urinary tract infection. Early infections were the
mmediate cause of death in 4 patients (10%).
Eighteen patients (45%) developed acute GVHD
t a median of 21 days (range, 7-69 days) after trans-
lantation. It was greater than grade II in only 3 cases
16%). The cumulative incidence of grades II to IV
cute GVHD was 42% (95% conﬁdence interval [CI],
9%-61%). High-dose steroids were used as ﬁrst-line
herapy for acute GVHD in 16 of these 18 patients.
he response rate to steroids was 82% and included
1 CRs (65%) and 3 PRs (17%).
Chronic GVHD was seen in 17 (45%) of the 31
valuable patients. It was limited in 10 cases (59%) and
xtensive in 7 cases (41%). The cumulative incidence
f chronic extensive GVHD at 1 year was 47% (95%
I, 31%-69%).
ransplant-Related Mortality
Five patients (12.5%) died before day 100 after
ransplantation because of transplant-related causes: 4
atients as a result of severe infections (80%) and 1
atient (20%) as a result of acute GVHD not respon-
ive to therapy. The cumulative incidence of 100-day
RM was 12.5% (95% CI, 5%-28%; Figure 1). Five
ore patients (14%) died after day 100, basically be-
0,0
0,2
0,4
0,6
0,8
1,0
0 12 24 36 48 60
Time from allo-RIC (months)
)I
C( 
M
R
T
1-yr TRM 25% (95%CI 13% - 43%) 
igure 1. Cumulative incidence of 100-day and 1-year transplant-
aelated mortality.
76ause of progressive chronic GVHD. The cumulative
ncidence of 1-year TRM was 25% (95% CI, 13%-
3%). Univariate analysis identiﬁed complementary
T before the allo-RIC (0% versus 42%; P .02) and
n Eastern Cooperative Oncology Group status 2 at
llo-RIC (32% versus 67%; P  .05) as signiﬁcant
rognostic factors (Table 3). Patients with neither risk
actor had a 1-year TRM of 0%, whereas in patients
ith both risk factors (n  5), TRM was as high as
0%  24% at 1 year after allo-RIC. Multivariate
nalysis identiﬁed the use of complementary RT be-
ore the allogeneic procedure as the only factor that
igniﬁcantly increased 1-year TRM (Table 4).
onor Lymphocyte Infusions
Eleven patients (27.5%) received at least 1 DLI
ecause of persistent disease or disease progression.
he median number of DLIs infused was 2 (range,
-6), and in 3 cases (27%) the DLI was preceded by
he administration of chemotherapy (NOVP [mitox-
able 3. Univariate Analyses of Prognostic Factors for Overall
urvival (OS), Event-Free Survival (EFS), and Progression-Free
urvival (PFS) at 2 Years and 1-Year Transplant-Related
ortality (TRM)
Prognostic Factor
No.
Patients
Results at
2 y
(95% CI)
P
Value
S
Disease status at allo-RIC
Sensitive disease 20 63% .05
Resistant disease 20 35%
FS
Remission duration after
ASCT
<12 mo 33% .05
>12 mo 6%
Disease status at allo-RIC
Sensitive disease 20 50% .01
Resistant disease 20 0%
FS
Remission duration after
ASCT
<12 mo 70% .05
>12 mo 0%
Disease status at allo-RIC
Sensitive disease 20 55% .007
Resistant disease 20 10%
RM
Complementary RT
before allo-RIC
No 47% .02
Yes 0%
COG status at allo-RIC
<2 67% .05
>2 32%
I indicates conﬁdence interval; allo-RIC, allogeneic stem cell
transplantation after a reduced-intensity conditioning protocol;
ASCT, autologous stem cell transplantation; RT, radiotherapy;
ECOG, Eastern Cooperative Oncology Group.ntrone, vincristine, vinblastine, prednisone] protocol
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Bn all 3 patients) to optimize disease control. The
esponse rate after DLI was 54%: 3 patients (27%)
chieved a CR, and 3 (27%) achieved a PR. Acute
VHD developed in 5 patients (46%) after DLIs: it
as greater than grade II in 2 patients. Chronic
VHD was seen in 5 cases (46%), 3 of whom had
reviously had acute GVHD.
isease Responses and Follow-Up
Disease status was evaluated at 3 months after
ransplantation. At this time point, 22 patients (55%)
ere in CR or very good PR, 5 patients (13%) were in
R, 4 patients (10%) were in stable disease, 4 (10%)
ere in progressive disease, and 5 (12%) had died
ecause of early TRM. The median follow-up of the
ntire series was 260 days (range, 9-1516 days). At the
ast follow-up, 22 patients (55%) were alive with a
edian follow-up of 376 days (range, 123-1516 days).
f these, 13 patients (32%) were alive without evi-
ence of disease progression, and 9 patients (23%) had
ctive disease. Eighteen patients (45%) had died, 6
20%) from disease progression and 10 (25%) from
RM.
When we analyzed the possible effect of the de-
elopment of acute and chronic GVHD on disease
ontrol after transplantation, we could demonstrate a
orderline signiﬁcant difference in terms of progres-
ion-free survival (PFS) between patients who devel-
ped extensive chronic GVHD and those who did
ot develop this complication after transplantation
71%  17% versus 44%  20%; P  .07; Figure 2).
Actuarial OS, EFS, and PFS at 2 years were 48% 
0%, 20%  7%, and 32%  10%, respectively (Fig-
re 3). The univariate analysis for the 3 survival end
oints analyzed is shown in Table 4. On multivariate
nalysis, the presence of chemorefractory disease was
he only adverse prognostic factor for OS, EFS, and
FS (Table 4): the 20 patients who allografted with
ensitive disease at the time of transplantation pre-
able 4. Adverse Prognostic Factors Inﬂuencing Overall Survival
OS), Event-Free Survival (EFS), Progression-Free Survival (PFS),
nd 1-Year Transplant-Related Mortality (TRM)
Prognostic Factor RR 95% CI P Value
S
Resistant disease at allo-RIC 2.3 1.0-6.1 .05
FS
Resistant disease at allo-RIC 2.5 1.2-5.6 .01
FS
Resistant disease at allo-RIC 3.8 1.3-10.9 .01
RM
Complementary RT before
allo-RIC 14.8 1.5-141.1 .01
R indicates relative risk; CI, conﬁdence interval; allo-RIC, allo-
geneic stem cell transplantation after a reduced-intensity con-
ditioning protocol; RT, radiotherapy.ented an actuarial OS, EFS, and PFS at 2 years of (
B & M T3%  12%, 33%  13%, and 55%  16%, respec-
ively (Figure 4).
More than 75% of the patients in our series were
llografted because of relapse after an ASCT. The
-year TRM was 24%. The 2-year OS, PFS, and EFS
ere 52%  11%, 34%  13%, and 23%  9%,
espectively. The only signiﬁcant prognostic factor in
he multivariate analysis was the duration of the re-
ission after the autologous procedure (12 versus
12 months). Especially good results were obtained
n patients allografted for late relapses after an ASCT
n  10 in our series), with 2-year OS, EFS, and PFS
f 75%  16%, 50%  17%, and 70%  18%,
espectively (Figure 5).
ISCUSSION
Conventional allo-SCT has proven to be a poten-
ially curative approach for diverse hematologic ma-
ignancies. Nevertheless, its availability is limited for
easons of age, availability of an HLA-compatible do-
or, and the presence of comorbidities in the recipi-
nt. Although conventional allo-SCT has been classi-
ally associated with an impressively high TRM
11,12], several other reports also indicate a possible
xistence of a graft-versus-HL effect [7-10], which
ould be of beneﬁt in terms of long-term disease
ontrol in some subgroups of patients who have a very
oor outcome with other conventional therapies, such
s autologous transplantation.
It has been well established that RIC protocols
ay offer a reduced risk of procedure-related mortal-
ty [13-15,32,33] compared with conventional trans-
lantation, and this may increase the percentage of
andidates for the allogeneic procedure by allowing
his procedure in older patients and in those with
Time from allo-RIC (months)
60483624120
)
%( 
S
F
P
100
80
60
40
20
0
No cGVHD + limited cGVHD,
n = 14, 44%±20% 
Extensive cGVHD, n = 7, 71%±17% 
p = 0.07
igure 2. Relationship between progression-free survival (PFS) and
atients developing extensive chronic graft-versus-host disease
cGVHD) after transplantation.
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1ther signiﬁcant comorbidities at the time of trans-
lantation [34]. The aim of this approach is to achieve
graft-versus-disease effect based on the alloreactivity
f donor T lymphocytes with a reduced TRM while
lso maintaining some antitumoral activity. In the case
f relapsed or refractory HL, RIC procedures could
e of beneﬁt in patients with a high risk of relapse by
educing the high TRM associated with the conven-
ional allogeneic procedure and, thus, allowing the
mergence of a clinically signiﬁcant graft-versus-HL
ffect. In this sense, the number of RIC transplanta-
ions has been progressively increasing in Europe in
he last 5 years.
With all these thoughts in mind, in 1999 the
panish Cooperative Group started a prospective pro-
ocol to analyze the feasibility of a reduced-intensity
rotocol in patients with hematologic malignancies
ho were not candidates for a conventional allo-SCT
33]. Taking into account the extremely poor results
n = 40,
Time from allo-RIC (months)
60483624120
)
%( 
S
O
100
80
60
40
20
0
n = 40, 48%±10%
Time from allo-RIC (months)
60483624120
)
%( 
S
F
P
100
80
60
40
20
0
n = 40, 32%±10%
igure 3. Actuarial 2-year overall survival (OS) (A), event-free survhown by the registry analyses [11,12], all patients e
78ith HL who fulﬁlled other inclusion criteria were
ncluded in the protocol, independently of age. Al-
hough the intensity of the myelosuppression of the
IC regimens widely differs from one protocol to the
ther [13-15,32], the combination of ﬂudarabine and
igh-dose melphalan was chosen because its immuno-
uppressive capacity is enough to allow a full alloge-
eic hematopoietic engraftment, but, at the same
ime, it provides a signiﬁcant antitumoral effect, which
ay be needed in some clinically aggressive diseases,
uch as HL, in which the graft-versus-lymphoma effect
oes not seem potent enough. The chosen GVHD pro-
hylaxis was the classic combination of CsA and short-
ourse MTX. It was thought that the more intensive
VHD prophylaxis combination could abrogate more
ggressively the development of acute GVHD after
ransplantation and, thus, the clinically associated graft-
ersus-malignancy effect, which is considered to be the
asis of this new approach. Allogeneic hematopoietic
Time from allo-RIC (months)
60483624120
100
80
60
40
20
0
n = 40, 19%±7%
S) (B), and progression-free survival (PFS) (C) of the entire series.)
%( 
S
F
Engraftment has not been a signiﬁcant pitfall of this
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Bombination. All the patients included in this trial but
showed a full donor chimerism when analyzed on
ay 28 after transplantation and were maintained as
ull chimeras during the complete follow-up. This
udarabine-melphalan combination has been previ-
usly reported by our group to achieve a high per-
entage of complete donor chimerism very rapidly
fter transplantation in relation to the ﬂudarabine-
usulfan combination [27], probably in part because of
he intense immunosuppression presented by the pa-
ients undergoing this conditioning protocol. The
.D. Anderson Cancer Center has also reported a
00% full donor chimerism for HL patients receiving
he ﬂudarabine-melphalan association but only a 50%
ull chimerism for those receiving the association of
Time from allo-RIC (months)
60483624120
)
%( 
S
O
100
80
60
40
20
0
Chemosensitive disease, 
n = 20, 63%±12% 
Chemorefractory disease
n = 20, 35%±13% 
p = 0.05 
Time from allo-RIC (months)
60483624120
)
%( 
S
F
P
100
80
60
40
20
0
Chemosensitive disease, 
n = 20, 55%±16% 
Chemorefractory disease, 
n = 20, 10%±9% 
p = 0.006 
igure 4. Differences in overall survival (OS) (A), event-free surviv
itive (n  20) and chemorefractory (n  20) patients.udarabine and cyclophosphamide [19]. Only 1 of our t
B & M Tatients developed a primary graft failure with an
utologous reconstitution demonstrated by means of
he polymerase chain reaction technique. This patient
ad a history of idiopathic thrombocytopenic purpura
nd Sjögren syndrome; although she was highly im-
unosuppressed before the allo-RIC, this autoim-
une situation could have contributed to the primary
raft rejection.
One of the main objectives of RIC protocols is the
eduction of transplant-related toxicities and, thus, the
ossibility of offering an allogeneic procedure to older
atients. In our group of patients, 8 (20%) were 45
ears at the time of transplantation, and, as previously
hown by other groups [19-23], in this protocol both
00-day and 1-year TRM (12.5% and 25%, respec-
Time from RIC-allo (months)
60483624120
)
%( 
S
F
E
100
80
60
40
20
0
Chemosensitive disease, 
n = 20, 33%±13% 
Chemorefractory disease, 
n = 20, 7%±6% 
p = 0.01 
) (B), and progression-free survival (PFS) (C) between chemosen-, 
al (EFSively) have been signiﬁcantly lower than what has
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1een previously reported for conventional allo-SCT
n refractory and relapsed HL [11,12]. However, these
esults will require longer follow-up for proper eval-
ation. This lower TRM in high-risk HL patients has
lso been reported by other groups: the M.D. Ander-
on group reported a 100-day TRM of 8% in a group
f 25 patients with high-risk HL who were treated
ith an RIC protocol consisting of the combination of
udarabine-melphalan or ﬂudarabine-cyclophospha-
ide, and the Fred Hutchinson Cancer Research
enter also reported an early TRM of 8% in a group
f 12 patients with HL treated with a less myelosup-
ressive regimen consisting of the combination of
udarabine and low-dose total body irradiation. This
RM increased to 22% at 1 year, basically because of
igure 5. Allo-RIC in patients who had a previously failed ASCT.
rogression-free survival (PFS) (C) are shown between late (n  1omplications related to the development of GVHD 1
80nd serious infectious episodes [22]. In our series, fatal
espiratory infections, which were more frequently
resent in patients who had previously received RT,
ere the leading cause of the signiﬁcantly higher
RM in this subgroup of patients. Early and late TRM
ere even more reduced in the context of an RIC pro-
ocol developed by the British Cooperative Group that
sed alemtuzumab as GVHD prophylaxis in combina-
ion with CsA. Peggs et al. [23] recently presented the
esults in a group of 49 patients with high-risk HL
reated with an RIC protocol that consisted of the com-
ination of ﬂudarabine and melphalan at the same doses
s those in the Spanish Cooperative protocol and the
ssociation of CsA at the usual doses plus alemtuzumab.
4.1% 100-day TRM was observed that increased to
nces in overall survival (OS) (A), event-free survival (EFS) (B), and
early (n  19) relapses.Differe6.3% at 730 days after the allogeneic procedure,
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Reduced-Intensity Conditioning Allogeneic Transplantation for Hodgkin Lymphoma
Baking into account the deaths directly related to DLIs
nd their complications.
Although one of the theoretical advantages that
as initially associated with RIC protocols was the
eduction of the incidence of acute GVHD after
ransplantation as a result of the reduction of tissue
amage produced by the conditioning protocol, this
as not been the case in practice. In fact, acute and
hronic GVHD and their directly related complica-
ions continue to be the leading causes of morbidity
nd mortality after these protocols [21,22], not only
or HL patients, but also for patients with other he-
atologic malignancies [14,15,33,34]. This higher-
han-expected GVHD incidence observed in these
IC protocols might reﬂect, at least in part, the older
ge, as well as the amount of therapy previously re-
eived before the allogeneic protocol. In our study,
cute GVHD was present in 45% of the series, al-
hough it was grade III or IV in only 16% of the patients.
hronic GVHD was also seen in a high percentage of
he evaluable patients (45%), although it was extensive in
nly 7 patients (41%). These incidences are similar to
hose reported by other authors [19,21,22], and these
omplications also constitute the main cause of mortality
n other series [22]. The use of alemtuzumab has also
igniﬁcantly reduced the incidences of both acute and
hronic GVHD; the British Cooperative Group has
eported a rate of acute GVHD grades II to IV of 16%
8 patients) in their group of 49 patients, and it re-
orted 7 cases of chronic GVHD (14%) (4 limited and
extensive) after allo-RIC [23].
Both the somewhat lower incidence of relapse in
atients developing extensive chronic GVHD and the
isease responses observed after DLIs (54% in our
tudy) suggest the existence of a graft-versus-HL ef-
ect, which is the most clinically important weapon of
he allogeneic procedure. This graft-versus-HL effect
as also been demonstrated in the alemtuzumab set-
ing of the British Cooperative Group trial [23]. In
heir recent report of 49 patients, they show a PFS of
6.3% for recipients of related allogeneic grafts and
2.6% for recipients of unrelated grafts at 4 years and
56% disease response to DLIs after transplantation
8 CRs and 1 PR). Clinical responses after DLIs were
ssociated with the development of GVHD after the
nfusion of lymphocytes.
Although the median OS of the surviving patients
f 1 year is still rather short, the 48%  10% 2-year
S and the 32% 10% 2-year PFS of our series of 40
atients are comparable to what has been published in
he literature [19,21-23]. These results were even bet-
er when we analyzed separately the patients who were
llografted in chemosensitive disease (63%  12%
nd 55%  16%, respectively). The disease response
o previous salvage chemotherapy has been the only
igniﬁcant prognostic factor for the 3 survival end
oints analyzed in this study. This has also been indi- F
B & M Tated by other authors [19,22] in the context of the
llo-RIC, and it is one of the major determinant prog-
ostic factors for other salvage therapies, eg, salvage
onventional chemotherapy and ASCT used in pa-
ients with relapsed or refractory HL. Nevertheless,
nd in our experience, even in chemorefractory pa-
ients, a signiﬁcant percentage of them (35%) become
ong-term survivors.
Especially good results, in terms of PFS, OS, and
-year TRM, have been obtained in patients treated
ith allo-RIC as salvage therapy for late relapses after
SCT. Similar results were suggested by Branson et
l. [35] in a group of 38 patients with lymphoprolif-
rative disorders treated with a Campath 1H (Scher-
ng AG, Berlin, Germany) RIC protocol after a pre-
ious ASCT failure.
The real effect of the allo-RIC procedure in re-
apsed or refractory HL is still unknown. It seems that
t clearly reduces TRM with respect to conventional
llo-SCT in this disease and, thus, improves outcome
n a similar subset of patients with a very bad progno-
is. A retrospective analysis of the Lymphoma Work-
ng Party of the European Group for Blood and Mar-
ow Transplantation comparing results between these
rocedures in a group of 247 patients (97 allo-RIC
nd 150 conventional allo-SCT) is ongoing [36].
oreover, many questions are still unanswered re-
arding this procedure: for example, the subgroups of
atients who could experience a clearer beneﬁt from it
re still unknown, as are the best conditioning proto-
ol and GVHD prophylaxis. The Spanish and British
ooperative Groups (ﬂudarabine and melphalan at
he same total doses but CsA plus MTX as GVHD
rophylaxis or CsA plus alemtuzumab) have per-
ormed a comparative study including 129 patients
ith lymphoproliferative disorders, recipients of a sib-
ing allogeneic transplantation and included in both
rospective trials [37]. At last follow-up, there was no
ifference in disease status between groups. Alemtu-
umab signiﬁcantly reduced the incidence of both
cute and chronic GVHD after transplantation but
ncreased the percentage of CMV reactivation after
ransplantation. Patients treated with alemtuzumab
ften required DLIs to achieve similar disease control.
speciﬁc analysis that includes patients with HL from
oth prospective trials is under way [38].
Another issue of clinical interest with a potential
nﬂuence on disease staging and the long-term out-
ome of these patients is the recent introduction of
ew functional imaging modalities, such as [18F]ﬂu-
rodeoxyglucose (FDG)–positron emission tomogra-
hy (PET). Most previous studies, including this one,
ave deﬁned response criteria both before transplan-
ation and during follow-up on the basis of conven-
ional radiographic characteristics [19,20,22]. The UK
ooperative Group has introduced for the ﬁrst time
DG-PET or the combined strategy of FDG-PET
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1nd conventional computed tomographic scanning in
he allogeneic setting [23]. Advantages of this tech-
ique include the more precise evaluation not only of
ossible candidates for the procedure, but also of dis-
ase response during follow-up, as well as early iden-
iﬁcation of potential candidates for DLIs. Neverthe-
ess, these beneﬁts need to be proven prospectively in
arger cohorts of patients.
In conclusion, allo-RIC is a feasible procedure for
atients with relapsed or refractory HL, with an ac-
eptable early and late TRM. Acute and chronic
VHD continue to be the major complications after
ransplantation and are responsible for a signiﬁcant
ercentage of patient deaths after the allogeneic pro-
edure. Nevertheless, the existence of responses after
he infusion of donor lymphocytes, of durable re-
ponses after transplantation, and of a somewhat lower
elapse rate in patients who develop extensive chronic
VHD indicates a clinically signiﬁcant graft-ver-
us-HL effect. OS seems promising, especially in che-
osensitive patients with allo-RIC. Nevertheless, more
atients included in prospective trials and longer fol-
ow-up are needed to really deﬁne the potential thera-
eutic role of allo-RIC in relapsed or refractory HL.
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